| 1 |
NCT03462680 |
Recruiting |
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures |
|
- Dietary Supplement: niacin
- Other: placebo
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Unified Parkinson's Disease Rating Scale (UPDRS) change
- Mini-Mental State Examination (MMSE) change
- Stroop test change
- (and 4 more...)
|
80 |
All |
35 Years and older (Adult, Older Adult) |
NCT03462680 |
N1613-I |
|
September 28, 2016 |
September 30, 2019 |
September 30, 2019 |
March 12, 2018 |
August 10, 2018 |
|
- Charlie Norwood VA Medical Center, Augusta, GA
Augusta, Georgia, United States
|
|
| 2 |
NCT03260166 |
Recruiting |
Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus |
- Cutaneous Lupus Erythematosus
- Systemic Lupus Erythematosus Rash
|
|
Interventional
|
Phase 2 |
- Second Xiangya Hospital of Central South University
- National Natural Science Foundation of China
- Hunan Provincial Natural Science Foundation of China
- National Key Clinical Specialty Construction Project of China
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- A change in Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI) activity score
- A change in RCLASI activity score
- Response Rate and Remarkable Response Rate at 1, 2, 3, 4, and 6 months, respectively
- (and 11 more...)
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03260166 |
PFK201707 |
|
August 31, 2017 |
August 2018 |
February 2019 |
August 24, 2017 |
September 25, 2017 |
|
- The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
|
|
| 3 |
NCT01984073 |
Recruiting |
Effects of Niacin On Fatty Acid Trapping |
|
- Drug: ER Niacin Oral Fat Challenge
- Drug: IR Niacin Oral Fat Challenge
- Other: Placebo Oral Fat Challenge
|
Interventional
|
Phase 1 |
- University of Pennsylvania
- National Heart, Lung, and Blood Institute (NHLBI)
- Arizona Pharmaceuticals Inc.
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
|
20 |
All |
22 Years to 75 Years (Adult, Older Adult) |
NCT01984073 |
NOFAT
K23HL091130 |
NOFAT |
December 2012 |
October 2018 |
October 2018 |
November 14, 2013 |
May 1, 2017 |
|
- Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States - Presbyterian Hospital
Philadelphia, Pennsylvania, United States
|
|
| 4 |
NCT03432871 |
Recruiting |
Nicotinamide Riboside and Mitochondrial Biogenesis |
- Mitochondrial Diseases
- Mitochondrial Myopathies
- Progressive External Ophthalmoplegia
- (and 6 more...)
|
- Dietary Supplement: Nicotinamide Riboside
|
Interventional
|
Not Applicable |
- Cambridge University Hospitals NHS Foundation Trust
- University of Cambridge
- MRC Mitochondrial Biology Unit
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Bioavailability
- Safety - Incidence of treatment related adverse events
- Safety - change in blood analytes
- (and 10 more...)
|
15 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03432871 |
A094351 |
|
December 8, 2017 |
December 31, 2018 |
May 30, 2019 |
February 14, 2018 |
March 16, 2018 |
|
- Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
|
|
| 5 |
NCT02322203 |
Recruiting |
Effects of Niacin Therapy on Lipoprotein Composition and Function |
|
- Dietary Supplement: Niacin Extended Release
|
Interventional
|
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Changes in protein or lipid composition of any lipoprotein fraction and changes in vascular compliance as measured by CAVI
|
200 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02322203 |
150042
15-H-0042 |
|
December 20, 2014 |
April 7, 2019 |
July 3, 2019 |
December 23, 2014 |
August 9, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 6 |
NCT03419364 |
Recruiting |
Study of Nicotinamide in Early Onset Preeclampsia |
|
|
Interventional
|
Phase 2 |
- University of North Carolina, Chapel Hill
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Mean Arterial blood Pressure (MAP)
- Number of participants with alanine aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)
- Number of participants with aspartate aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)
- (and 7 more...)
|
25 |
Female |
18 Years to 55 Years (Adult) |
NCT03419364 |
17-0693
1R03HD092370-01 |
|
November 1, 2017 |
December 31, 2019 |
December 31, 2019 |
February 1, 2018 |
February 1, 2018 |
|
- UNC at Chapel Hill
Chapel Hill, North Carolina, United States
|
|
| 7 |
NCT03061474 |
Recruiting |
Nicotinamide as an Early Alzheimer's Disease Treatment |
- Alzheimer's Disease
- Mild Cognitive Impairment
|
- Drug: Nicotinamide
- Drug: Placebo Comparator
|
Interventional
|
Phase 2 |
- University of California, Irvine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in p-tau 231
- Change in p-tau 181
- Change in total tau
|
48 |
All |
50 Years and older (Adult, Older Adult) |
NCT03061474 |
20163246 |
NEAT |
July 12, 2017 |
February 28, 2019 |
February 28, 2019 |
February 23, 2017 |
February 15, 2018 |
|
- University of California, Irvine
Irvine, California, United States - University of California, Los Angeles
Los Angeles, California, United States
|
|
| 8 |
NCT03423342 |
Recruiting |
Nicotinamide Riboside in Systolic Heart Failure |
|
- Dietary Supplement: nicotinamide riboside
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- University of Washington
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
- Effect of NR on Whole Blood NAD+ Levels
- Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
- Effect of NR on Mitochondrial Function
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03423342 |
STUDY00001830
1R21HL126209-01 |
|
May 19, 2016 |
December 1, 2018 |
June 30, 2019 |
February 6, 2018 |
August 1, 2018 |
|
- University of Washington
Seattle, Washington, United States
|
|
| 9 |
NCT03501433 |
Recruiting |
Effects of Nicotinamide Riboside on Metabolism and Vascular Function |
|
- Dietary Supplement: Nicotinamide riboside chloride (Niagen)
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- NAD+
- Vasodilatory responsiveness
- Lipdemia
- Oxidative stress and inflammation
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03501433 |
17-603 |
|
February 1, 2018 |
December 2018 |
December 2018 |
April 18, 2018 |
April 18, 2018 |
|
- Iowa State University
Ames, Iowa, United States
|
|
| 10 |
NCT03163576 |
Not yet recruiting |
The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis |
|
- Drug: Niacin
- Drug: Phosphate Binder
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the level of phosphorous level in haemodialysis patients treated by niacin
|
150 |
All |
18 Years to 60 Years (Adult) |
NCT03163576 |
ENPD |
|
June 2017 |
June 2019 |
December 2019 |
May 23, 2017 |
May 23, 2017 |
|
|
|
| 11 |
NCT03151707 |
Recruiting |
The Effects of Nicotinamide Riboside Supplementation on NAD+/NADH Ratio and Bioenergetics |
|
- Drug: Nicotinamide Riboside
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline to the end of treatment in brain NAD+/NADH ratio
- Change from baseline to the end of treatment in brain phosphocreatine (PCr) to adenosine triphosphate (ATP) ratio (PCr/ATP)
- Change from baseline to the end of treatment in creatine kinase (CK) enzyme rate
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03151707 |
2017P000006 |
|
October 1, 2017 |
July 2019 |
July 2019 |
May 12, 2017 |
July 11, 2018 |
|
- Cagri Yuksel
Belmont, Massachusetts, United States
|
|
| 12 |
NCT02416739 |
Recruiting |
Anticancer Activity of Nicotinamide on Lung Cancer |
- Non-Small-Cell Lung Carcinoma
|
|
Interventional
|
Phase 2
Phase 3 |
- Il Yeong Park, Ph.D.
- Chungbuk National University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Hazard ratio (PFS) of the nicotinamide arm to the placebo arm
- Response rate
- Difference in quality of life between the nicotinamide arm and the placebo arm
- Overall survival
|
110 |
All |
18 Years and older (Adult, Older Adult) |
NCT02416739 |
Amina-X-002 |
|
March 2015 |
February 2019 |
February 2019 |
April 15, 2015 |
July 18, 2018 |
|
- Chonnam National University Hwasun Hospital
Hwasun, Chonnam, Korea, Republic of
|
|
| 13 |
NCT03356483 |
Not yet recruiting |
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. |
- Obsessive-Compulsive Disorder
|
- Drug: Psilocybin (0.25mg/kg)
- Drug: Niacin (250mg)
|
Interventional
|
Phase 2 |
- Yale University
- Heffter Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in severity of OCD symptoms, which will be measured by The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). The Primary Outcome Measure will be collected at baseline and 48 hours, assessing change from baseline at 48 hours.
- Acute Yale-Brown Obsessive-Compulsive Scale (A-YBOCS)
- Changes in brain connectivity, which will be measured with functional Magnetic Imaging Resonance (fMRI).
- (and 21 more...)
|
30 |
All |
21 Years to 55 Years (Adult) |
NCT03356483 |
2000020355 |
|
October 2, 2018 |
January 2022 |
July 2022 |
November 29, 2017 |
July 4, 2018 |
|
- Connecticut Mental Health Center
New Haven, Connecticut, United States
|
|
| 14 |
NCT03568968 |
Not yet recruiting |
A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study |
|
- Dietary Supplement: Nicotinamide Riboside
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Haukeland University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease rating Scale)
- NAD metabolism
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03568968 |
2018/597 |
|
October 1, 2018 |
October 1, 2020 |
October 1, 2021 |
June 25, 2018 |
June 25, 2018 |
|
|
|
| 15 |
NCT02950441 |
Recruiting |
Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype |
|
- Dietary Supplement: Nicotinamide Riboside
- Other: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mitochondrial function assessment in skeletal muscle using high resolution respirometry
- Skeletal muscle NAD+ levels in vastus lateralis biopsy using targeted metabolomics
- Improvement in response to oral glucose tolerance test/HOMA-IR
- (and 6 more...)
|
12 |
Male |
70 Years to 80 Years (Older Adult) |
NCT02950441 |
RG_15-152 |
NADMet |
June 2016 |
September 2018 |
September 2019 |
November 1, 2016 |
June 7, 2017 |
|
- University Hospitals Birmingham NHS Foundation Trust
Birmingham, West Midlands, United Kingdom
|
|
| 16 |
NCT02835664 |
Recruiting |
Nicotinamide Riboside and Metabolic Health |
- Obesity
- Insulin Resistance
|
- Dietary Supplement: Nicotinamide Riboside (Niagen)
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Maastricht University Medical Center
- Dutch Heart Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Insulin sensitivity: muscle- and liver specific
- Muscle mitochondrial function (ex vivo)
- Ectopic lipid accumulation
- (and 5 more...)
|
15 |
All |
45 Years to 65 Years (Adult, Older Adult) |
NCT02835664 |
NL58119.068.16 |
|
December 2016 |
December 2018 |
December 2018 |
July 18, 2016 |
April 6, 2018 |
|
- Maastricht University Medical Centre
Maastricht, Netherlands
|
|
| 17 |
NCT03562468 |
Recruiting |
A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults |
- Cognitive Function
- Mood
- Sleep
|
- Dietary Supplement: 300 mg/day of TRU NIAGEN (nicotinamide riboside)
- Dietary Supplement: 1000 mg/day of TRU NIAGEN (nicotinamide riboside)
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- ChromaDex, Inc.
- Midwest Center for Metabolic and Cardiovascular Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- The primary comparison will be the low dose (300 mg/d nicotinamide riboside) condition to the placebo condition for the change from baseline to the end of each relevant treatment period.
|
40 |
All |
55 Years and older (Adult, Older Adult) |
NCT03562468 |
MB-1801 |
|
June 13, 2018 |
March 2019 |
March 2019 |
June 19, 2018 |
July 31, 2018 |
|
- MB Clinical Research
Boca Raton, Florida, United States
|
|
| 18 |
NCT02109614 |
Recruiting |
Early Aortic Valve Lipoprotein(a) Lowering Trial |
- Aortic Stenosis and Lipoprotein(a) Levels
|
- Drug: Extended release Niacin
- Drug: Placebo Comparator
|
Interventional
|
Early Phase 1 |
- George Thanassoulis
- Jewish General Hospital
- Laval University
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Calcium score progression by cardiac CT in individuals randomized to niacin as compared to those randomized to placebo
- Mean change in Lp(a) levels between treatment arms
|
238 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT02109614 |
A00-M105-13A |
EAVaLL |
May 2014 |
January 2017 |
September 2017 |
April 10, 2014 |
September 13, 2016 |
|
- MUHC - Montreal General Hospital
Montreal, Quebec, Canada - MUHC - Royal Victoria Hospital
Montreal, Quebec, Canada - Jewish General Hospital
Montreal, Quebec, Canada
|
|
| 19 |
NCT02812238 |
Recruiting |
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity |
- Atherosclerosis
- Diabetes
- Coronary Artery Disease
|
- Dietary Supplement: Nicotinamide riboside (NR)
- Other: Placebo
|
Interventional
|
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- The refeeding IL-1 secretion in response to inflammasome stimulation in the NR treatment arm versus the same subject's response on the placebo treatment arm using paired t-test analyses
|
42 |
All |
18 Years to 39 Years (Adult) |
NCT02812238 |
160129
16-H-0129 |
|
June 23, 2016 |
March 5, 2019 |
March 5, 2019 |
June 24, 2016 |
August 9, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 20 |
NCT03579693 |
Not yet recruiting |
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease |
- Chronic Kidney Disease
- Sarcopenia
- Frailty
|
- Dietary Supplement: CoQ10
- Dietary Supplement: Nicotinamide riboside
- Dietary Supplement: Placebo
|
Interventional
|
Phase 2 |
- University of Washington
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Maximal Aerobic Capacity- CoQ10
- Maximal Aerobic Capacity- NR
- Maximal Aerobic Capacity- Placebo
- (and 33 more...)
|
30 |
All |
30 Years to 79 Years (Adult, Older Adult) |
NCT03579693 |
STUDY00004998
R01DK101509 |
CoNR |
August 2018 |
January 2020 |
April 2020 |
July 6, 2018 |
July 10, 2018 |
|
- University of Washington
Seattle, Washington, United States
|
|
| 21 |
NCT02702492 |
Recruiting |
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) |
|
- Drug: KPT-9274
- Drug: KPT-9274 & Niacin ER
|
Interventional
|
Phase 1 |
- Karyopharm Therapeutics Inc
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
175 |
All |
18 Years and older (Adult, Older Adult) |
NCT02702492 |
KCP-9274-901 |
PANAMA |
June 2016 |
June 2019 |
November 2019 |
March 8, 2016 |
May 3, 2018 |
|
- University of Colorado Cancer Center
Aurora, Colorado, United States - Georgetown University, Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States - Mayo Clinic Rochester
Rochester, Minnesota, United States - (and 4 more...)
|
|
| 22 |
NCT03540758 |
Recruiting |
Regulation of Endogenous Glucose Production by Central KATP Channels |
- Type 2 Diabetes Mellitus
- Glucose Metabolism Disorders
- Glucose, High Blood
|
- Drug: Diazoxide
- Drug: Nicotinic acid
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Albert Einstein College of Medicine, Inc.
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Endogenous glucose production (EGP)
|
45 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03540758 |
2018-9039
R01DK069861 |
|
June 2018 |
November 2020 |
November 2021 |
May 30, 2018 |
May 31, 2018 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States
|
|
| 23 |
NCT02942888 |
Recruiting |
The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition |
- Mild Cognitive Impairment
- NAD
|
- Dietary Supplement: Nicotinamide riboside
- Dietary Supplement: Sugar Pill
|
Interventional
|
Not Applicable |
- The University of Texas Health Science Center at San Antonio
- University of Texas
- South Texas Veterans Health Care System
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- Change in Cognitive Assessment - Montreal Cognitive Assessment (MoCA) - from baseline at 10 weeks
- Change in cerebral blood flow from baseline at 10 weeks
- Change in plasma NAD from baseline at 10 weeks
- (and 9 more...)
|
26 |
All |
65 Years and older (Older Adult) |
NCT02942888 |
HSC20160350H |
NAD |
November 30, 2017 |
December 2018 |
December 2018 |
October 24, 2016 |
January 9, 2018 |
|
- South Texas Veterans Healthcare System (STVHCS)
San Antonio, Texas, United States - University of Texas Health San Antonio
San Antonio, Texas, United States
|
|
| 24 |
NCT02721537 |
Recruiting |
Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Athletes |
|
- Dietary Supplement: Nicotinamide Riboside
- Other: Matching placebo
|
Interventional
|
Not Applicable |
- Mayo Clinic
- University of Minnesota - Clinical and Translational Science Institute
- Thorne Research Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Screening
|
- Change in brain NAD+ levels
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT02721537 |
15-006870 |
TRMC-004 |
September 2016 |
December 2018 |
June 2019 |
March 29, 2016 |
February 23, 2018 |
|
- University of Minnesota Center for Magnetic Resonance Research
Minneapolis, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 25 |
NCT03176628 |
Recruiting |
Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study |
|
- Dietary Supplement: Basis
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Elysium Health
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Maximum plasma concentration [Cmax] of NR
- Maximum plasma concentration [Cmax] of pterostilbene
- Area Under the Curve [AUC] of NR
- (and 6 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03176628 |
2017P000908 |
BAKIS |
November 1, 2017 |
October 31, 2018 |
October 31, 2018 |
June 5, 2017 |
March 27, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 26 |
NCT02808182 |
Recruiting |
Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D) |
- Impaired Glucose Tolerance
|
- Drug: Nicotinic acid
- Other: [7,7,8,8-2H]-palmitate
- Other: [U-13C]-palmitate
- (and 2 more...)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Plasma NEFA appearance rate
- Cardiac uptake
- WAT spillover NEFA appearance rates
- (and 9 more...)
|
40 |
All |
45 Years to 65 Years (Adult, Older Adult) |
NCT02808182 |
2016-1196 |
AGL11 |
January 17, 2017 |
May 2018 |
February 2019 |
June 21, 2016 |
February 7, 2017 |
|
- centre de recherche du CHUS
Sherbrooke, Quebec, Canada
|
|
| 27 |
NCT03151239 |
Recruiting |
Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function |
- Glucose Metabolism Disorders
|
- Dietary Supplement: NMN supplement
- Other: Placebo
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- To determine change in insulin sensitivity.
- To determine change in beta-cell function.
|
50 |
Female |
55 Years to 75 Years (Adult, Older Adult) |
NCT03151239 |
201701096 |
NMN |
July 1, 2017 |
June 1, 2019 |
June 1, 2020 |
May 12, 2017 |
May 2, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 28 |
NCT03268902 |
Recruiting |
Early Life Interventions for Childhood Growth and Development In Tanzania |
- Malnutrition
- Stunting
- Cognitive Development
- Enteric Pathogens
|
- Drug: Azithromycin Oral Liquid Product
- Drug: Nitazoxanide Oral Suspension
- Dietary Supplement: Nicotinamide
- Drug: Placebos
|
Interventional
|
Phase 2
Phase 3 |
- Haydom Lutheran Hospital
- University of Virginia
- Bill and Melinda Gates Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Height-for-age z-score (HAZ) at 18 months
- Weight-for-age z-score (WAZ) at 18 months
- Head circumference-for-age z-score (HCAZ) at 18 months
- (and 16 more...)
|
1188 |
All |
up to 14 Days (Child) |
NCT03268902 |
19465 |
ELICIT |
September 5, 2017 |
September 2020 |
December 2020 |
August 31, 2017 |
September 12, 2017 |
|
- Haydom Lutheran Hospital
Haydom, Manyara, Tanzania
|
|
| 29 |
NCT03635411 |
Not yet recruiting
New |
Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET) |
|
- Dietary Supplement: Nicotinamide Riboside and pterostilbene
- Drug: Placebo
|
Interventional
|
Phase 1 |
- University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Complications
- Grip Strength Scores
- Inhalation Volume Measurements
- (and 13 more...)
|
48 |
All |
65 Years and older (Older Adult) |
NCT03635411 |
829947 |
BestBet |
September 2018 |
December 2019 |
January 2020 |
August 17, 2018 |
August 17, 2018 |
|
|
|
| 30 |
NCT03482167 |
Not yet recruiting |
NAD+ Therapy for Improving Memory and Cerebrovascular Function in Patients With MCI |
- Mild Cognitive Impairment
|
- Drug: Niagen®
- Other: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- University of Delaware
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in cognitive scores at 12 weeks
- Change from baseline in cerebrovascular reactivity at 12 weeks
- Change from baseline in total brain blood flow at 12 weeks
- (and 2 more...)
|
58 |
All |
60 Years to 90 Years (Adult, Older Adult) |
NCT03482167 |
1079271-1
K01AG054731 |
|
June 2018 |
March 2022 |
March 2022 |
March 29, 2018 |
March 29, 2018 |
|
- Neurovascular Aging Laboratory
Newark, Delaware, United States
|
|
| 31 |
NCT03565328 |
Not yet recruiting |
The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects |
|
- Dietary Supplement: Niagen
|
Interventional
|
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- NR enhancement of mitochondrial function in skeletal muscle
- effects of NR on oxidative phosphorylation and inflammation in respective subject primary skin fibroblasts
- quantitative serum cytokine immunoassay profiling to assess whether NR blunts HF linked inflammation
- (and 2 more...)
|
50 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03565328 |
180107
18-H-0107 |
|
August 22, 2018 |
June 1, 2021 |
June 1, 2021 |
June 21, 2018 |
August 17, 2018 |
|
- Walter Reed National Military Medical Center
Bethesda, Maryland, United States - National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 32 |
NCT03019666 |
Recruiting |
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL |
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- (and 5 more...)
|
- Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of any grade 4 or greater suspected adverse reaction
- Occurrence of Grade III or IV acute graft-versus-host disease (aGVHD)
- Occurrence of treatment related mortality (TRM)
- (and 2 more...)
|
24 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03019666 |
2015LS057
MT2015-46 |
|
October 18, 2017 |
April 30, 2019 |
March 31, 2020 |
January 12, 2017 |
June 7, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 33 |
NCT03110432 |
Recruiting |
Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry |
|
- Drug: PCSK9 Inhibitor [EPC]
- Drug: Standard lipid lowering therapy
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- LDL cholesterol goal achievement
- LDL cholesterol reduction
- Number of treatment changes
|
2000 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03110432 |
PERI-DYS |
PERI-DYS |
May 18, 2017 |
December 30, 2020 |
February 16, 2021 |
April 12, 2017 |
August 3, 2017 |
|
- Medizinische Klinik und Poliklinik III
Dresden, Germany
|
|
| 34 |
NCT03313297 |
Recruiting |
Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) |
- Diabetes Mellitus, Type 2
|
- Drug: AZD4017
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Skin 11β-HSD1 activity
- Urinary cortisol / cortisone metabolites
- AZD4017 in plasma
- (and 12 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03313297 |
ED17/93260 |
GC-SHealD |
April 10, 2018 |
September 12, 2018 |
September 28, 2018 |
October 18, 2017 |
May 11, 2018 |
|
- Leeds Teaching Hospitals Trust
Leeds, United Kingdom
|
|
| 35 |
NCT03360435 |
Recruiting |
Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients |
- Bariatric Surgery Candidate
- Vitamin Deficiency
- Mineral Deficiency
|
- Dietary Supplement: Patch MD MultiVitamin Plus patch
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of subjects with deficiencies
- Thiamine
- Pyridoxine
- (and 15 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03360435 |
IRB201701809 |
|
December 15, 2017 |
November 18, 2019 |
November 18, 2019 |
December 4, 2017 |
June 1, 2018 |
|
- University of Florida
Gainesville, Florida, United States
|
|
| 36 |
NCT02537392 |
Recruiting |
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease |
|
- Dietary Supplement: Vitamin B Complex and Folic Acid
- Dietary Supplement: Iron and Folic Acid
- Dietary Supplement: Folic Acid
|
Interventional
|
Not Applicable |
- Health Science Center of Xi’an Jiaotong University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Neonatal pulse oximetry oxygen saturation measured by pulse oximetry
- Incidence of congenital heart disease and the subtypes
- Incidence of birth defects and the subtypes
- (and 9 more...)
|
9374 |
Female |
15 Years to 49 Years (Child, Adult) |
NCT02537392 |
NSFC81230016 |
|
September 2015 |
December 2018 |
June 2019 |
September 1, 2015 |
January 13, 2017 |
|
- Xi'an Jiaotong University College of Medicine
Xi'an, Shaanxi, China
|
|
| 37 |
NCT03622541 |
Recruiting
New |
Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3 Internal Tandem Duplication (ITD) |
|
|
Interventional
|
Phase 2 |
- The University of Hong Kong
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03622541 |
AML004 |
|
November 15, 2010 |
November 2018 |
November 2019 |
August 9, 2018 |
August 9, 2018 |
|
- The University of Hong Kong
Hong Kong, Hong Kong
|
|
| 38 |
NCT03606590 |
Recruiting
New |
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) |
|
- Device: NovoTTF-100L(P) device
- Drug: Sorafenib
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- In-field control rate at one year
- Overall survival
- (and 5 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT03606590 |
EF-30 |
|
August 2018 |
December 2020 |
December 2020 |
July 31, 2018 |
August 8, 2018 |
|
- Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
|
|
| 39 |
NCT03582618 |
Recruiting |
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma |
- Hepatocellular Carcinoma
- Advanced Cancer
|
- Drug: Sorafenib
- Drug: CVM-1118
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Overall survival (OS)
- Progression-free survival (PFS)
- (and 13 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03582618 |
CVM-004 |
|
July 12, 2018 |
December 2020 |
June 2021 |
July 11, 2018 |
July 30, 2018 |
|
- Charleston Hematology Oncology Associates
Charleston, South Carolina, United States - National Cheng Kung University Hospital
Tainan, Taiwan
|
|
| 40 |
NCT03565536 |
Recruiting |
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer |
- Thyroid Cancer, Anaplastic
|
- Drug: Nexavar
- Procedure: operation
- Radiation: External radiation therapy
|
Interventional
|
Phase 2 |
- Fujian Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Thyroglobulin
- CT assessment
- Length of contact surface between tumor and common carotid artery
- (and 6 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03565536 |
UTC-NEXAVAR |
|
May 1, 2018 |
April 30, 2019 |
October 30, 2019 |
June 21, 2018 |
June 21, 2018 |
|
- Fujian Medical University Union Hospital
FuZhou, Fujian, China
|
|
| 41 |
NCT03535259 |
Recruiting |
Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma |
- Hepatocellular Carcinoma, Radiotherapy, Sorafenib
|
- Radiation: concurrent sorafenib and IMRT, followed sorafenib maintenance
|
Interventional
|
Phase 2 |
- Chinese Academy of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MST
- ORR
- TTP
- Rate of III-IV grade adverse events
|
86 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03535259 |
NCC201803020 |
SIRAHCC |
April 20, 2018 |
April 1, 2019 |
April 1, 2021 |
May 24, 2018 |
May 24, 2018 |
|
- Bo Chen
Beijing, Beijing, China
|
|
| 42 |
NCT03518502 |
Recruiting |
Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis |
- Hepatocellular Carcinoma
- Metastasis
|
- Procedure: transarterial chemoembolization (TACE)
- Drug: Sorafenib
|
Interventional
|
Phase 4 |
- Korea University
- Korean Liver Cancer Study Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Time to progression (TTP)
- Progression free survival (PFS)
- Median survival time (MST)
|
130 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03518502 |
2012AS0313 |
|
March 1, 2012 |
February 28, 2020 |
February 28, 2022 |
May 8, 2018 |
May 8, 2018 |
|
- Korea University Ansan Hospital
Ansan, Gyeonggi-do, Korea, Republic of - Soonchunghyang University Bucheon Hospital
Bucheon, Gyeonggi-do, Korea, Republic of - Keimyung University Dongsan Hospital
Daegu, Korea, Republic of - (and 3 more...)
|
|
| 43 |
NCT03412773 |
Recruiting |
Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC |
- Hepatocellular Carcinoma (HCC)
|
- Drug: BGB-A317
- Drug: Sorafenib
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Safety Run-In Substudy[Japan only]: Percentage of patients with adverse events
- Safety Run-In Substudy[Japan only]: Percentage of patients with dose-limiting toxicities (DLT) [Determination of the pivotal Phase 3 dose of BGB-A317 in Japanese patients]
- (and 25 more...)
|
660 |
All |
18 Years and older (Adult, Older Adult) |
NCT03412773 |
BGB-A317-301 |
|
December 28, 2017 |
January 2022 |
May 2022 |
January 26, 2018 |
June 28, 2018 |
|
- St. Jude Heritage Healthcare
Fullerton, California, United States - Ingalls Memorial Hospital
Harvey, Illinois, United States - Healthcare Research Network III, LLC
Tinley Park, Illinois, United States - (and 32 more...)
|
|
| 44 |
NCT03236649 |
Not yet recruiting |
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
- Hepatocellular Carcinoma (HCC)
|
- Drug: Icaritin
- Drug: Sorafenib Tosylate Tablets
|
Interventional
|
Phase 3 |
- Beijing Shenogen Biomedical Co., Ltd
- Chinese Academy of Medical Sciences
- NanJing PLA 81 Hospital
- (and 27 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Time to progress（TTP）
- (and 4 more...)
|
200 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03236649 |
SNG1705ICR-2 |
|
August 30, 2017 |
August 2019 |
August 2019 |
August 2, 2017 |
August 2, 2017 |
|
|
|
| 45 |
NCT03178656 |
Recruiting |
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis |
- Portal Vein Tumor Thrombus
|
- Drug: Sorafenib
- Procedure: surgery
|
Interventional
|
Phase 4 |
- Huazhong University of Science and Technology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Prevention
|
- overall survival of 1 year
- overall survival of 3 year
- time to progression
|
54 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT03178656 |
chenxp007 |
|
December 15, 2016 |
April 15, 2018 |
December 15, 2019 |
June 7, 2017 |
December 21, 2017 |
|
- Hepatic surgery center, Tong ji Hospital
Wuhan, Hubei, China
|
|
| 46 |
NCT03140332 |
Recruiting |
Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib. |
- Hepatocellular Carcinoma
- Perfusion Scanner
|
- Other: Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib
|
Interventional
|
Not Applicable |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Scannographic evaluation of tumor response with mRECIST criteria
|
75 |
All |
18 Years and older (Adult, Older Adult) |
NCT03140332 |
PI2016_843_0025 |
HCC-CTPerf |
February 27, 2017 |
February 27, 2020 |
February 27, 2020 |
May 4, 2017 |
August 8, 2018 |
|
- CHU Amiens Picardie
Amiens, Picardie, France
|
|
| 47 |
NCT03097848 |
Recruiting |
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma |
|
- Procedure: RFA
- Drug: Sorafenib
|
Interventional
|
Not Applicable |
- Southwest Hospital, China
- Chengdu PLA General Hospital
- Sichuan Provincial People's Hospital
- (and 11 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival
- Time To Recurrence
- Overall Survival
- (and 3 more...)
|
450 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03097848 |
SWHB 019 |
ESCALATOR |
May 4, 2017 |
December 30, 2018 |
December 31, 2018 |
March 31, 2017 |
May 8, 2017 |
|
- Southwest Hospital
Chongqing, Chongqing, China
|
|
| 48 |
NCT02988440 |
Recruiting |
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients |
|
- Drug: PDR001
- Drug: Sorafenib
|
Interventional
|
Phase 1 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse Events (AEs) as a measure of safety and tolerability
- Pharmacokinetics (PK): Ctrough
- Pharmacokinetics (PK): Cmax
- (and 9 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02988440 |
CPDR001G2101
2016-004131-20 |
|
April 20, 2017 |
December 30, 2018 |
July 18, 2019 |
December 9, 2016 |
November 17, 2017 |
|
- Karmanos Cancer Institute
Detroit, Michigan, United States - Novartis Investigative Site
Montreal, Quebec, Canada - Novartis Investigative Site
Clichy, France - (and 5 more...)
|
|
| 49 |
NCT02867280 |
Recruiting |
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection |
- Hepatocellular Carcinoma
- Recurrence
|
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence free survival
- Time To Recurrence
- Recurrence rate
- (and 3 more...)
|
400 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02867280 |
Sorafenib-MVI |
|
June 2016 |
June 2023 |
June 2023 |
August 15, 2016 |
August 15, 2016 |
|
- Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
|
|
| 50 |
NCT02856126 |
Recruiting |
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC |
|
- Procedure: Hepatic arterial infusion chemotherapy
- Procedure: Transarterial chemoembolization
- Drug: TACE regimen
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Sun Yat-sen University
- Kaiping Central Hospital
- First Affiliated Hospital, Sun Yat-Sen University
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Progress free survival
- Adverse Events
- Number of of Patients developed Adverse Events
|
214 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02856126 |
HCC-S022 |
|
August 2016 |
August 2018 |
August 2018 |
August 4, 2016 |
November 17, 2017 |
|
- Dongguan People's Hospital
Dongguan, Guangdong, China - Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, China - The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China - (and 4 more...)
|
|
| 51 |
NCT02834546 |
Recruiting |
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma |
- Hepatocellular Carcinoma (HCC)
|
- Biological: Sorafenib plasma concentration 4 weeks after treatment initiation
|
Observational
|
|
- University Hospital, Bordeaux
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Adverse events related to Sorafenib needing a dose adjustment or a symptomatic medication
- Adverse events notification
- Radiological response assessed by scan or MRI
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02834546 |
CHUBX 2014/25 |
ACTES |
July 25, 2017 |
November 2018 |
October 2019 |
July 15, 2016 |
November 13, 2017 |
|
- Institut Bergonié
Bordeaux, France - CHU de Limoges
Limoges, France - CHU de Montpellier
Montpellier, France - (and 2 more...)
|
|
| 52 |
NCT02794337 |
Recruiting |
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer |
- Carcinoma, Hepatocellular
|
- Radiation: SBRT
- Procedure: TACE
- Drug: Sorafenib
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- In-field Progression Free Survival
- Cause Specific Survival
- Response assessment after treatment
- (and 2 more...)
|
386 |
All |
18 Years and older (Adult, Older Adult) |
NCT02794337 |
TMC IEC III 91 |
TACE-SBRT |
December 2014 |
January 2019 |
January 2022 |
June 9, 2016 |
June 9, 2016 |
|
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre
Navi Mumbai, Maharashtra, India - Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre
Navi Mumbai, Maharashtra, India
|
|
| 53 |
NCT02733809 |
Recruiting |
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
|
|
Interventional
|
Phase 4 |
- King Saud University
- King Faisal Specialist Hospital & Research Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Overall and disease-free survival genes.
- The predictors of survival ( response to Sorafenib )
- Potential genetic targets for resistance.
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT02733809 |
KSULDRCSSMH001 |
|
January 2014 |
December 2024 |
December 2024 |
April 12, 2016 |
August 22, 2017 |
|
- King Saud University Medical City
Riyadh, Saudi Arabia
|
|
| 54 |
NCT02642913 |
Recruiting |
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients |
|
- Drug: Enzalutamide
- Drug: Enzalutamide with Sorafenib
|
Interventional
|
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Astellas Pharma US, Inc.
- Mayo Clinic
- (and 6 more...)
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
|
73 |
All |
18 Years and older (Adult, Older Adult) |
NCT02642913 |
15-279 |
|
December 2015 |
December 2018 |
December 2018 |
December 30, 2015 |
October 12, 2017 |
|
- University of California San Francisco
San Francisco, California, United States - Washington University School of Medicine
Saint Louis, Missouri, United States - Roswell Park Cancer Institute
Buffalo, New York, United States - (and 2 more...)
|
|
| 55 |
NCT02636426 |
Recruiting |
Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study |
|
|
Interventional
|
Phase 1 |
- VU University Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the maximum tolerated plasma AUC0-12h of high-dose, pulsatile sorafenib
- AUC0-12h of sorafenib and its primary active metabolite pyridine-N-oxide (escalation cohorts)
- Cmax of sorafenib and its primary active metabolite pyridine-N-oxide (escalation cohorts)
- (and 6 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT02636426 |
2015.224 |
SOPRANO |
September 2015 |
December 2017 |
December 2017 |
December 21, 2015 |
March 20, 2017 |
|
- VU University Medical Center
Amsterdam, Noord-Holland, Netherlands
|
|
| 56 |
NCT02562755 |
Recruiting |
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone |
- Hepatocellular Carcinoma (HCC)
|
- Biological: Pexastimogene Devacirepvec (Pexa Vec)
- Drug: Sorafenib
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Time to Progression (TTP)
- Progression Free Survival (PFS)
- (and 4 more...)
|
600 |
All |
18 Years and older (Adult, Older Adult) |
NCT02562755 |
JX594-HEP024 |
PHOCUS |
October 2015 |
October 2018 |
October 2019 |
September 29, 2015 |
August 6, 2018 |
|
- University of Alabama
Birmingham, Alabama, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - UC Irvine Medical Center
Orange, California, United States - (and 115 more...)
|
|
| 57 |
NCT02354898 |
Recruiting |
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma |
- Advanced Solid Tumors
- Hepatocellular Carcinoma
|
- Drug: BBI503
- Drug: Sorafenib
|
Interventional
|
Phase 1 |
- Sumitomo Dainippon Pharma Co., Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine of the Maximum Tolerated Dose (MTD) of BBI503 monotherapy and in combination with Sorafenib by assessing dose-limiting toxicities (DLTs)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Pharmacokinetic profile of BBI503
- (and 3 more...)
|
60 |
All |
20 Years and older (Adult, Older Adult) |
NCT02354898 |
DA101003 |
|
March 2015 |
March 2019 |
|
February 3, 2015 |
May 9, 2017 |
|
- 5 Sites
Chiba, etc., Japan
|
|
| 58 |
NCT03263624 |
Not yet recruiting |
Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease |
|
- Device: fractional carbon dioxide laser
- Drug: Tazarotene Cream 0.1%
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- percentage of clinically improved patients using modified nail psoriasis severity index.
|
30 |
All |
Child, Adult, Older Adult |
NCT03263624 |
ltns |
|
October 1, 2017 |
October 1, 2018 |
November 1, 2018 |
August 28, 2017 |
August 28, 2017 |
|
|
|
| 59 |
NCT02279719 |
Recruiting |
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma |
|
- Drug: BBI608
- Drug: BBI503
- Drug: Sorafenib
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs) (Phase 1 portion)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Assessment of the preliminary anti-tumor activity by performing tumor assessments every 8 weeks (Phase 2 portion)
- (and 2 more...)
|
114 |
All |
18 Years and older (Adult, Older Adult) |
NCT02279719 |
BBIHCC-103
BBI608-503-103HCC |
|
December 2014 |
December 2018 |
|
October 31, 2014 |
February 12, 2018 |
|
- Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - Mayo Clinic
Phoenix, Arizona, United States - Southern California Research Center
Coronado, California, United States - (and 30 more...)
|
|
| 60 |
NCT03337360 |
Recruiting |
The Impact of a Nutritional Supplement (Impryl®) on Male Fertility |
|
- Dietary Supplement: Impryl
- Other: Placebo
|
Interventional
|
Not Applicable |
- Radboud University
- Goodlife Fertility B.V.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Ongoing pregnancy rate
- Overall pregnancy rate
- Time to pregnancy 1 - start intervention
- (and 7 more...)
|
1200 |
Male |
18 Years to 50 Years (Adult) |
NCT03337360 |
NL61414.091.17
NTR6551 |
SUMMER |
April 23, 2018 |
April 1, 2020 |
April 1, 2021 |
November 9, 2017 |
June 5, 2018 |
|
- Canisius-Wilhelmina Hospital
Nijmegen, Gelderland, Netherlands - Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands - Gelre Ziekenhuizen
Apeldoorn, Netherlands - (and 11 more...)
|
|
| 61 |
NCT02187081 |
Recruiting |
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC |
|
- Procedure: radiofrequency ablation plus Sorafenib
- Procedure: Radiofrequency ablation
|
Interventional
|
Not Applicable |
- Southwest Hospital, China
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- 2-year incidence of tumor recurrence
- Overall survival
- 1-year incidence of recurrence
- (and 5 more...)
|
380 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02187081 |
SWHB008 |
|
March 15, 2017 |
December 2018 |
December 2018 |
July 10, 2014 |
March 28, 2017 |
|
- Southwest Hospital
Chongqing, Chongqing, China
|
|
| 62 |
NCT02185560 |
Recruiting |
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib |
|
- Drug: Sorafenib (Nexavar, BAY43-9006)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Number of participants with Adverse drug reaction as a measure of safety and tolerability.
- Number of participants with Serious adverse events as a measure of safety and tolerability.
- Number of participants with Serious adverse drug reaction as a measure of safety and tolerability
- (and 2 more...)
|
443 |
All |
Child, Adult, Older Adult |
NCT02185560 |
17391
NEXAVAR-TC-01 |
JPMS-DTC |
June 27, 2014 |
March 31, 2020 |
June 30, 2021 |
July 9, 2014 |
July 30, 2018 |
|
- Multiple Locations, Japan
|
|
| 63 |
NCT01906216 |
Recruiting |
Sorafenib Chemoembolization Evaluation Controlled Trial |
|
- Drug: Sorafenib
- Procedure: TACE
|
Interventional
|
Phase 2
Phase 3 |
- Fourth Military Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Time to progression
- Tumor response
- Adverse events
|
246 |
All |
18 Years and older (Adult, Older Adult) |
NCT01906216 |
XHDD-001 |
SELECT |
September 2013 |
September 2018 |
December 2018 |
July 24, 2013 |
July 24, 2018 |
|
- Xijing Hospital of Digestive Disease
Xi`an, Shaanxi, China
|
|
| 64 |
NCT01730937 |
Recruiting |
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer |
- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Recurrent Adult Primary Liver Cancer
|
- Drug: sorafenib tosylate
- Radiation: stereotactic body radiation therapy
|
Interventional
|
Phase 3 |
- Radiation Therapy Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- TTP
- PFS
- (and 3 more...)
|
368 |
All |
18 Years and older (Adult, Older Adult) |
NCT01730937 |
RTOG 1112
NCI-2012-02057
U10CA021661 |
|
April 2013 |
June 2020 |
June 2025 |
November 21, 2012 |
April 10, 2018 |
|
- USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - UCSF Medical Center-Mount Zion
San Francisco, California, United States - University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States - (and 29 more...)
|
|
| 65 |
NCT01724606 |
Recruiting |
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) |
- Breast Cancer
- Brain Metastases
|
- Radiation: Whole Brain Radiotherapy (WBRT)
- Drug: Sorafenib
|
Interventional
|
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Bayer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose
- assessing toxicity by the number of adverse events
- CNS progression-free survival
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT01724606 |
12-046 |
|
November 2012 |
November 2018 |
November 2018 |
November 12, 2012 |
December 5, 2017 |
|
- Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - (and 3 more...)
|
|
| 66 |
NCT01470495 |
Recruiting |
Combined Treatment of RFA and Sorafenib on Recurrent HCC |
- HCC
- Radiofrequency Ablation
- Sorafenib
|
- Other: RFA + Sorafenib
- Other: RFA
|
Interventional
|
Not Applicable |
- Southwest Hospital, China
- Hunan Province Tumor Hospital
- Tang-Du Hospital
- (and 11 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Care Provider, Outcomes Assessor)
- Primary Purpose: Other
|
- time interval between new lessions emerging after the first HCC recurrence
- 3-year overrall survival
|
430 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01470495 |
swhb005 |
REPEAT |
January 2015 |
December 2018 |
December 2018 |
November 11, 2011 |
March 28, 2017 |
|
- Institute of hepatobiliary surgery,southwest hospital
Chongqing, Chongqing, China
|
|
| 67 |
NCT01444807 |
Recruiting |
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases |
- Metastatic Renal Cell Carcinoma
|
|
Interventional
|
Phase 2 |
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Recurrence Free Survival
- Overall Survival
- Safety Profile
- Vascular endothelial growth factors (VEGF) levels in BSC and Sorafenib arm.
|
132 |
All |
18 Years and older (Adult, Older Adult) |
NCT01444807 |
GP1 |
|
December 2011 |
March 2017 |
September 2019 |
October 3, 2011 |
March 22, 2017 |
|
- Istituto Tumori Milano
Milan, Mi, Italy - Cinzia Ortega
Alba, Italy - Alessandra Bearz
Aviano, Italy - (and 11 more...)
|
|
| 68 |
NCT01141478 |
Recruiting |
Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria |
- Carcinoma, Hepatocellular
|
- Radiation: Proton Beam Radiotherapy
- Drug: Sorafenib
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- To assess the radiological progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
|
220 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01141478 |
5100104 |
|
August 2010 |
June 2017 |
June 2018 |
June 10, 2010 |
November 4, 2016 |
|
- Loma Linda University Medical Center
Loma Linda, California, United States
|
|
| 69 |
NCT03143946 |
Recruiting |
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor |
|
- Dietary Supplement: Vitamin supplement;
- Other: Diet advice
|
Interventional
|
Not Applicable |
- University Medical Center Groningen
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the change in the proportion of patients with normal vitamin values
- nutrition state
- distress
- (and 3 more...)
|
53 |
All |
18 Years and older (Adult, Older Adult) |
NCT03143946 |
201600626 |
|
December 2016 |
December 2018 |
December 2018 |
May 8, 2017 |
April 27, 2018 |
|
- University Medical Center Groningen
Groningen, Netherlands
|
|
| 70 |
NCT03310034 |
Recruiting |
NAD Supplementation Study |
- Aging
- Mitochondrial Function
|
- Dietary Supplement: NAD-precursors
- Dietary Supplement: Control
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Ex vivo mitochondrial respiration
- Basal metabolic rate
- In vivo mitochondrial capacity
- (and 5 more...)
|
14 |
All |
65 Years to 75 Years (Older Adult) |
NCT03310034 |
NL61204.068.17 |
NADS |
November 1, 2017 |
December 2019 |
December 2019 |
October 16, 2017 |
October 16, 2017 |
|
- Maastricht University
Maastricht, Limburg, Netherlands
|
|
| 71 |
NCT03510715 |
Not yet recruiting |
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia |
|
- Drug: Alirocumab SAR236553 (REGN727)
- Drug: Rosuvastatin
- Drug: Ezetimibe
- (and 9 more...)
|
Interventional
|
Phase 3 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent change in LDL-C
- Percent change in Apo B
- Percent change in non-HDL-C
- (and 9 more...)
|
18 |
All |
8 Years to 17 Years (Child) |
NCT03510715 |
EFC14660
2017-002297-39
U1111-1200-2046 |
|
August 3, 2018 |
August 2019 |
June 2020 |
April 27, 2018 |
July 25, 2018 |
|
|
|
| 72 |
NCT03510884 |
Recruiting |
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia |
|
- Drug: Alirocumab SAR236553 (REGN727)
- Drug: Rosuvastatin
- Drug: Atorvastatin
- (and 10 more...)
|
Interventional
|
Phase 3 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percent change in low-density lipoprotein cholesterol (LDL-C)
- Percent change in LDL-C
- Percent change in Apo B
- (and 11 more...)
|
150 |
All |
8 Years to 17 Years (Child) |
NCT03510884 |
EFC14643
2017-001903-60
U1111-1193-0721 |
|
May 31, 2018 |
February 2022 |
March 2022 |
April 27, 2018 |
August 3, 2018 |
|
- Investigational Site Number 8400001
Boca Raton, Florida, United States - Investigational Site Number 1240003
Winnipeg, Canada - Investigational Site Number 7100001
Pretoria, South Africa
|
|
| 73 |
NCT03287882 |
Recruiting |
Effect of Micronutrients and Life Skills Education on the Health and Nutrition of Adolescent and Young Women in Pakistan |
- Adolescents
- Anemia
- Pregnancy
- Empowerment
|
- Dietary Supplement: Multiple micronutrients (UNIMMAP composition)
- Behavioral: Life skills based education
|
Interventional
|
Phase 3 |
- Aga Khan University
- The Hospital for Sick Children
- National Program for Family Planning and Primary Health Care
- Bill and Melinda Gates Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Anemia status
- Low birth weight
- Biomarkers: serum ferritin, serum transferrin receptor, hepcidin, serum retinol, serum 25(OH)D, alpha-glycolytic protein, C-reactive protein (women)
- (and 20 more...)
|
25400 |
Female |
15 Years to 24 Years (Child, Adult) |
NCT03287882 |
4324-Ped-ERC-16 |
|
June 30, 2017 |
April 30, 2020 |
April 30, 2021 |
September 19, 2017 |
September 19, 2017 |
|
- Matiari Research and Training Centre
Matiari, Sindh, Pakistan
|
|
| 74 |
NCT03533712 |
Not yet recruiting |
Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome in Houndé District, Burkina Faso. |
- Small for Gestational Age at Delivery
- Low Birth Weight
- Prematurity
- Infant Malnutrition
|
- Dietary Supplement: Fortified balanced energy-protein (BEP) supplement
- Dietary Supplement: Fe and folic acid supplement
|
Interventional
|
Phase 4 |
- University Ghent
- Harvard School of Public Health
- Institut de Recherche en Sciences de la Sante, Burkina Faso
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Small-for-Gestational-age (SGA)
- Length-for-age Z-scores (LAZ)
- Birth length
- (and 9 more...)
|
1776 |
Female |
15 Years to 35 Years (Child, Adult) |
NCT03533712 |
OPP1175213 |
MISAME-3 |
May 2018 |
May 2021 |
May 2022 |
May 23, 2018 |
May 23, 2018 |
|
- Houndé district
Houndé, Tuy, Burkina Faso
|
|
| 75 |
NCT02989870 |
Recruiting |
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma |
- HepatoCellular Carcinoma
- Unresectable HepatoCellular Carcinoma
- Liver Cancer
|
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
- Drug: Sorafenib
- Drug: Bavituximab
|
Interventional
|
Phase 1 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Comprehensive Cancer Network
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of Treatment Related Adverse Events
- Objective Response Rate (ORR)
- Progression Free Survival (PFS)
- Overall Survival (OS)
|
18 |
All |
18 Years and older (Adult, Older Adult) |
NCT02989870 |
MCC-18924 |
|
March 27, 2017 |
January 31, 2020 |
January 31, 2021 |
December 12, 2016 |
June 6, 2018 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 76 |
NCT02560779 |
Recruiting |
Trial of TRC105 and Sorafenib in Patients With HCC |
|
- Drug: TRC105
- Drug: Sorafenib
|
Interventional
|
Phase 1
Phase 2 |
- Tracon Pharmaceuticals Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose of TRC105 in Combination with Sorafenib (Phase 1b).
- Preliminary evidence of antitumor activity when TRC105 is added to sorafenib will be assessed by Overall Response Rate (ORR). (Phase 1b)
- Preliminary evidence of antitumor activity when TRC105 is added to sorafenib will be assessed by Progression-Free Survival (PFS). (Phase 1b)
- (and 4 more...)
|
39 |
All |
18 Years and older (Adult, Older Adult) |
NCT02560779 |
105HCC101 |
|
November 2016 |
September 2018 |
September 2018 |
September 25, 2015 |
October 12, 2017 |
|
- City of Hope
Duarte, California, United States
|
|
| 77 |
NCT03211416 |
Recruiting |
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer |
- Advanced Adult Hepatocellular Carcinoma
- Child-Pugh Class A
- Stage III Hepatocellular Carcinoma
- (and 6 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Drug: Sorafenib Tosylate
|
Interventional
|
Phase 1
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors
- Overall survival
- Time to tumor progression
|
27 |
All |
18 Years and older (Adult, Older Adult) |
NCT03211416 |
I 35316
NCI-2017-01114
P30CA016056 |
|
September 13, 2017 |
October 11, 2018 |
October 11, 2019 |
July 7, 2017 |
June 5, 2018 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 78 |
NCT03037437 |
Recruiting |
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer |
|
- Drug: Sorafenib (SOR)
- Drug: Hydroxychloroquine (HCQ)
|
Interventional
|
Phase 2 |
- The University of Texas Health Science Center at San Antonio
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to tumor progression evaluated via tumor imaging
|
68 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03037437 |
CTMS 16-0076
HSC20160515H |
|
February 16, 2017 |
December 2018 |
December 2018 |
January 31, 2017 |
January 31, 2018 |
|
- University of Texas Health Cancer Center
San Antonio, Texas, United States
|
|
| 79 |
NCT02748304 |
Recruiting |
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma |
|
- Other: control
- Drug: sorafenib
- Drug: aspirin
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Overall survival
- Disease free survival
- Number of patients with treatment-related bleedings who use aspirin
|
150 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02748304 |
Huashan 003 |
|
April 2016 |
June 2019 |
June 2021 |
April 22, 2016 |
October 11, 2016 |
|
- Huashan hospital
Shanghai, China
|
|
| 80 |
NCT02672488 |
Recruiting |
Metformin Plus Sorafenib for Advanced HCC |
|
- Drug: Sorafenib
- Drug: Metformin
|
Interventional
|
Phase 2 |
- Tianjin Medical University Cancer Institute and Hospital
- First Affiliated Hospital of Harbin Medical University
- Harbin Medical University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Time To Progression
- Progression Free Survival
- Objective Response Rate
|
82 |
All |
18 Years and older (Adult, Older Adult) |
NCT02672488 |
METSOR |
|
December 2015 |
December 2017 |
December 2018 |
February 3, 2016 |
February 3, 2016 |
|
- Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
|
|
| 81 |
NCT02624700 |
Recruiting |
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer |
- Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer
|
- Drug: Pemetrexed
- Drug: Sorafenib
|
Interventional
|
Phase 2 |
- Virginia Commonwealth University
- Eli Lilly and Company
- Bayer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The percentage of objective response either Partial Response (PR) or Complete Response(CR).
- The percentage of progression-free survival (PFS).
- To determine the 2-year survival rate after initial study treatment.
- The amount of reported Adverse events (AEs).
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT02624700 |
MCC-14-10790
HM20005967
NCI-2015-02190 |
|
January 28, 2016 |
December 31, 2019 |
December 31, 2019 |
December 8, 2015 |
April 18, 2018 |
|
- Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
|
|
| 82 |
NCT02529761 |
Recruiting |
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma |
|
- Drug: Sorafenib
- Procedure: TACE
|
Interventional
|
Not Applicable |
- Fourth Military Medical University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Time to progression
- Tumor response
- (and 2 more...)
|
330 |
All |
18 Years and older (Adult, Older Adult) |
NCT02529761 |
S-T 002 |
|
August 2015 |
August 2018 |
October 2018 |
August 20, 2015 |
September 22, 2015 |
|
- Xijing Hospital of digestive disease, Fourth Military Medical University
Xi'an, Shaanxi, China
|
|
| 83 |
NCT02436902 |
Recruiting |
Adjuvant Therapies for Patients With HCC and MVI |
|
- Procedure: TACE
- Drug: Sorafenib
- Drug: TACE plus sorafenib
- Procedure: transarterial chemotherapy plus embolization
|
Interventional
|
Phase 3 |
- Guangxi Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survivals
- Hospital mortality
- Recurrence rates
|
240 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02436902 |
A-TACE/S-HCC |
A-TACE/S-HCC |
February 2016 |
August 2018 |
August 2019 |
May 7, 2015 |
June 12, 2017 |
|
- Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University
Nanning, Guangxi, China
|
|
| 84 |
NCT02330783 |
Recruiting |
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients |
- Metastatic Renal Cell Carcinoma
|
- Drug: Bevacizumab
- Drug: Sorafenib
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progress-free survival,PFS
- overall survival,OS
- Safety: adverse events
|
106 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02330783 |
BCH-RCC-141201 |
|
December 2014 |
December 2018 |
December 2018 |
January 5, 2015 |
May 9, 2017 |
|
- Sun Yat-sen university cancer center
Guangzhou, Guangdong, China - Peking University First Hospital
Beijing, China - Beijing Cancer Hospital
Beijing, China - Cancer Hospital, Fudan University
Shanghai, China
|
|
| 85 |
NCT02292173 |
Recruiting |
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer |
- Hepatocellular Cancer
- Liver Cancer
|
- Drug: Trametinib
- Drug: Sorafenib
|
Interventional
|
Phase 1 |
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Progression Free Survival (PFS)
- Response Rate
- Overall Survival (OS)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT02292173 |
MCC-17932 |
|
December 19, 2014 |
April 2019 |
April 2020 |
November 17, 2014 |
May 1, 2018 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 86 |
NCT02143401 |
Recruiting |
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors |
- Cirrhosis
- Hepatitis B Infection
- Hepatitis C Infection
- (and 6 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Navitoclax
- Other: Pharmacological Study
- Drug: Sorafenib Tosylate
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of navitoclax
- Incidence of adverse events as graded per NCI CTCAE v. 4.0
- Tumor response using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1
- (and 5 more...)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT02143401 |
NCI-2014-01043
MC1315
9608
UM1CA186686 |
|
November 7, 2014 |
November 1, 2018 |
|
May 21, 2014 |
August 3, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of Colorado Hospital
Aurora, Colorado, United States - (and 7 more...)
|
|
| 87 |
NCT02129322 |
Not yet recruiting |
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 |
|
- Drug: Sorafenib
- Drug: S-1
- Drug: Oxaliplatin
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to Recurrence (TTR)
- Overall survival (OS)
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02129322 |
ZYYYMedOncoLT01 |
|
July 2015 |
June 2017 |
December 2019 |
May 2, 2014 |
August 11, 2015 |
|
- First affiliated hospital, Zhejiang University
Hangzhou, China
|
|
| 88 |
NCT03325491 |
Recruiting |
Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance |
- Impaired Mitochondrial Function, Muscle Performance
|
- Dietary Supplement: Acipimox
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- University of Exeter
- Royal Devon and Exeter NHS Foundation Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in mitochondrial function
- Chronic changes in habitual muscle protein synthetic rates
|
20 |
Male |
65 Years to 75 Years (Older Adult) |
NCT03325491 |
1617/024 |
Rejuvenate2 |
March 7, 2018 |
October 1, 2018 |
December 31, 2018 |
October 30, 2017 |
May 16, 2018 |
|
- NIHR Exeter Clinical Research Facility
Exeter, Devon, United Kingdom
|
|
| 89 |
NCT02792621 |
Recruiting |
Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men |
- Impaired Mitochondrial Function, Muscle Performance
|
- Dietary Supplement: Acipimox
- Dietary Supplement: placebo
|
Interventional
|
Not Applicable |
- Royal Devon and Exeter NHS Foundation Trust
- University of Exeter
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in mitochondrial function
- Chronic changes in habitual muscle protein synthetic rates
|
20 |
Male |
65 Years to 75 Years (Older Adult) |
NCT02792621 |
R&D no 1608287 |
Rejuvenate |
November 8, 2016 |
June 8, 2018 |
December 8, 2018 |
June 7, 2016 |
April 11, 2018 |
|
- NIHR Exeter Clinical Research Facility
Exeter, Devon, United Kingdom
|
|
| 90 |
NCT02422368 |
Not yet recruiting |
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease |
|
- Drug: Methylprednisolone + ASTED
- Drug: Methylprednisolone +Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Iran University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Mean of total eye score changes (using NOSPECS severity score)
- Mean of "thyroid eye disease Quality of life" score changes (Using TED-QOL)
- Mean of clinical activity score changes (CAS Score)
- (and 2 more...)
|
110 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02422368 |
93-02-124-24581 |
|
September 2018 |
June 2020 |
June 2021 |
April 21, 2015 |
July 24, 2018 |
|
- Private Thyroid eye disease clinic
Tehran, Iran, Islamic Republic of - Rassoul Akram Hospital
Tehran, Iran, Islamic Republic of
|
|
| 91 |
NCT02567981 |
Recruiting |
Comparison of Two Nutrition Interventions in Young Children in El Salvador |
|
- Dietary Supplement: 21 micronutrient-fortified supplement
- Dietary Supplement: Cereal Fortificado (Fortified Cereal)
- Dietary Supplement: Ferrous sulphate
- Dietary Supplement: Vitamin A
|
Interventional
|
Not Applicable |
- The Mathile Institute for the Advancement of Human Nutrition
- Fundación Salvadoreña para la Salud y el Desarrollo Humano
- Humanitas Global Development
- Ministry of Health, El Salvador
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in mean hemoglobin concentrations
- Prevalence of anemia
- Changes in mean length/height-for age z-scores (HAZ)
- (and 16 more...)
|
4000 |
All |
6 Months to 59 Months (Child) |
NCT02567981 |
11-08 |
|
September 2015 |
September 2020 |
September 2020 |
October 5, 2015 |
November 7, 2016 |
|
- FUSAL
Santa Elena, El Salvador
|
|
| 92 |
NCT03468231 |
Recruiting |
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC |
|
- Drug: Sorafenib
- Drug: HAIC of FOLFOX
- Drug: HAIC of OXA
|
Interventional
|
Phase 3 |
- Sun Yat-sen University
- First Affiliated Hospital, Sun Yat-Sen University
- Dongguan People's Hospital
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival
- Progress free survival
- Adverse Events
- (and 2 more...)
|
300 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03468231 |
HCC-20180309 |
|
March 9, 2018 |
September 9, 2019 |
March 9, 2020 |
March 16, 2018 |
March 16, 2018 |
|
- Dongguan People's Hospital
Dongguan, Guangdong, China - Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, China - The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China - (and 4 more...)
|
|
| 93 |
NCT03439891 |
Recruiting |
Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer |
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v7
- (and 4 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- Drug: Sorafenib
|
Interventional
|
Phase 2 |
- University of California, San Francisco
- Bayer
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) (Part 1)
- Overall response rate (ORR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Part 2)
- Duration of response (DOR)
- (and 5 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03439891 |
174523
NCI-2018-00051
17-23590
P30CA082103 |
|
February 21, 2018 |
May 29, 2020 |
December 31, 2020 |
February 20, 2018 |
March 7, 2018 |
|
- University of California, San Francisco
San Francisco, California, United States
|
|
| 94 |
NCT03170895 |
Recruiting |
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD |
|
- Drug: Sorafenib
- Drug: Omacetaxine Mepesuccinate Injection
|
Interventional
|
Phase 2 |
- The University of Hong Kong
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03170895 |
AML008 |
|
July 1, 2017 |
November 1, 2020 |
October 1, 2021 |
May 31, 2017 |
July 19, 2017 |
|
- The University of Hong Kong
Hong Kong, Hong Kong
|
|
| 95 |
NCT03164382 |
Recruiting |
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma |
- Liver Cancer
- Hepatic Carcinoma
|
- Drug: FOLFOX regimen
- Drug: Sorafenib 200Mg Tab
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Overall survival
- Time to Progression
- Time to Intrahepatic tumor Progression
|
130 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03164382 |
SB5010-2017-015 |
|
January 1, 2017 |
December 31, 2019 |
December 31, 2022 |
May 23, 2017 |
May 30, 2017 |
|
- Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center,
Guangzhou, Guangdong, China
|
|
| 96 |
NCT03009461 |
Recruiting |
Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis |
- HepatoCellular Carcinoma
- Portal Vein Thrombosis
|
- Procedure: HAIC
- Drug: Sorafenib
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
62 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03009461 |
MPVTT |
|
June 1, 2017 |
December 2019 |
December 2019 |
January 4, 2017 |
June 28, 2017 |
|
- Peking University Cancer Hospital
Beijing, Beijing, China
|
|
| 97 |
NCT02981498 |
Recruiting |
Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma |
|
- Procedure: Hepatic arterial infusion chemotherapy
- Drug: Folfox Protocol
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival rate
- Objective response
- OS
- AE event
|
35 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02981498 |
HCC-S027 |
|
June 2015 |
April 2017 |
April 2017 |
December 5, 2016 |
March 14, 2017 |
|
- Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China
|
|
| 98 |
NCT02747537 |
Recruiting |
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan |
|
- Drug: Sorafenib
- Drug: Irinotecan
|
Interventional
|
Phase 2 |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Time to progression (TTP)
- Toxicity as measured by grade, frequency, and relatedness of adverse events per CTCAE version 4.0
|
30 |
All |
24 Months to 21 Years (Child, Adult) |
NCT02747537 |
201605006 |
|
June 24, 2016 |
January 31, 2020 |
February 29, 2020 |
April 21, 2016 |
February 15, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 99 |
NCT02716766 |
Recruiting |
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) |
- Carcinoma, Hepatocellular
- Secondary
|
- Drug: Sorafenib
- Drug: Capecitabine
- Drug: Oxaliplatin
|
Interventional
|
Phase 2 |
- The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to progression (TTP)
- Objective Response Rate (ORR)
- Progression-free survival (PFS)
- (and 2 more...)
|
138 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02716766 |
HKU-MONC-HCC-001 |
|
March 2016 |
December 2018 |
December 2020 |
March 23, 2016 |
May 30, 2017 |
|
- Queen Mary Hospital
Hong Kong, Hong Kong
|
|
| 100 |
NCT02349867 |
Recruiting |
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer |
- Pancreatic Adenocarcinoma
- Stage IA Pancreatic Cancer
- Stage IB Pancreatic Cancer
- (and 4 more...)
|
- Drug: Gemcitabine
- Drug: Sorafenib
- Drug: Vorinostat
- (and 4 more...)
|
Interventional
|
Phase 1 |
- Virginia Commonwealth University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase 2 dose and schedule
- Incidence of adverse events using National Cancer Institute CTCAE v4.0
- Surgical mortality for patients who received chemoradiation
- (and 5 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT02349867 |
MCC-12-07328
NCI-2015-00017
P30CA016059 |
|
January 29, 2015 |
May 1, 2019 |
May 1, 2021 |
January 29, 2015 |
December 2, 2017 |
|
- Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
|
|
Create an RSS feed from your search for:
Download the search results for: